scPharmaceuticals Inc.
scPharmaceuticals Inc. SCPH Peers
See (SCPH) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SCPH | $3.52 | +9.32% | 185.83M | -1.83 | -$1.92 | N/A |
| VRTX | $440.66 | +0.46% | 113.16B | -115.36 | -$3.82 | N/A |
| REGN | $596.54 | +0.37% | 63.32B | 15.16 | $39.34 | +0.15% |
| SGEN | $228.74 | -0.07% | 43.15B | -57.19 | -$4.00 | N/A |
| ALNY | $291.86 | +2.30% | 38.06B | -138.32 | -$2.11 | N/A |
| ARGX | $578.10 | +2.20% | 35.30B | 35.25 | $16.40 | N/A |
| BNTX | $97.80 | +5.42% | 23.51B | -27.47 | -$3.56 | N/A |
| BGNE | $184.71 | +0.49% | 20.21B | -22.55 | -$8.19 | N/A |
| RPRX | $34.25 | +0.68% | 19.29B | 13.98 | $2.45 | +2.53% |
| DNA-WT | $0.27 | -2.76% | 18.73B | N/A | N/A | N/A |
Stock Comparison
SCPH vs VRTX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, VRTX has a market cap of 113.16B. Regarding current trading prices, SCPH is priced at $3.52, while VRTX trades at $440.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas VRTX's P/E ratio is -115.36. In terms of profitability, SCPH's ROE is -7.54%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, SCPH is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs REGN Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, REGN has a market cap of 63.32B. Regarding current trading prices, SCPH is priced at $3.52, while REGN trades at $596.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas REGN's P/E ratio is 15.16. In terms of profitability, SCPH's ROE is -7.54%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SCPH is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs SGEN Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, SGEN has a market cap of 43.15B. Regarding current trading prices, SCPH is priced at $3.52, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SCPH's ROE is -7.54%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, SCPH is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ALNY Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ALNY has a market cap of 38.06B. Regarding current trading prices, SCPH is priced at $3.52, while ALNY trades at $291.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ALNY's P/E ratio is -138.32. In terms of profitability, SCPH's ROE is -7.54%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, SCPH is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ARGX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ARGX has a market cap of 35.30B. Regarding current trading prices, SCPH is priced at $3.52, while ARGX trades at $578.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ARGX's P/E ratio is 35.25. In terms of profitability, SCPH's ROE is -7.54%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, SCPH is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs BNTX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, BNTX has a market cap of 23.51B. Regarding current trading prices, SCPH is priced at $3.52, while BNTX trades at $97.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas BNTX's P/E ratio is -27.47. In terms of profitability, SCPH's ROE is -7.54%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, SCPH is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs BGNE Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, BGNE has a market cap of 20.21B. Regarding current trading prices, SCPH is priced at $3.52, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SCPH's ROE is -7.54%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, SCPH is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs RPRX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, RPRX has a market cap of 19.29B. Regarding current trading prices, SCPH is priced at $3.52, while RPRX trades at $34.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas RPRX's P/E ratio is 13.98. In terms of profitability, SCPH's ROE is -7.54%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, SCPH is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs DNA-WT Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, DNA-WT has a market cap of 18.73B. Regarding current trading prices, SCPH is priced at $3.52, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SCPH's ROE is -7.54%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, SCPH is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs SMMT Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, SMMT has a market cap of 16.78B. Regarding current trading prices, SCPH is priced at $3.52, while SMMT trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas SMMT's P/E ratio is -66.91. In terms of profitability, SCPH's ROE is -7.54%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, SCPH is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs UTHR Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, UTHR has a market cap of 13.77B. Regarding current trading prices, SCPH is priced at $3.52, while UTHR trades at $305.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas UTHR's P/E ratio is 12.16. In terms of profitability, SCPH's ROE is -7.54%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SCPH is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs KRTX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, KRTX has a market cap of 12.60B. Regarding current trading prices, SCPH is priced at $3.52, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SCPH's ROE is -7.54%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, SCPH is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs GMAB Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, GMAB has a market cap of 12.51B. Regarding current trading prices, SCPH is priced at $3.52, while GMAB trades at $20.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas GMAB's P/E ratio is 11.87. In terms of profitability, SCPH's ROE is -7.54%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, SCPH is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs INCY Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, INCY has a market cap of 12.35B. Regarding current trading prices, SCPH is priced at $3.52, while INCY trades at $63.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas INCY's P/E ratio is 319.05. In terms of profitability, SCPH's ROE is -7.54%, compared to INCY's ROE of +0.01%. Regarding short-term risk, SCPH is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs EXEL Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, EXEL has a market cap of 12.19B. Regarding current trading prices, SCPH is priced at $3.52, while EXEL trades at $44.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas EXEL's P/E ratio is 20.41. In terms of profitability, SCPH's ROE is -7.54%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, SCPH is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs BMRN Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, BMRN has a market cap of 11.39B. Regarding current trading prices, SCPH is priced at $3.52, while BMRN trades at $59.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas BMRN's P/E ratio is 22.00. In terms of profitability, SCPH's ROE is -7.54%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, SCPH is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs MRNA Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, MRNA has a market cap of 10.21B. Regarding current trading prices, SCPH is priced at $3.52, while MRNA trades at $26.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas MRNA's P/E ratio is -3.02. In terms of profitability, SCPH's ROE is -7.54%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, SCPH is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ASND Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ASND has a market cap of 9.68B. Regarding current trading prices, SCPH is priced at $3.52, while ASND trades at $160.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ASND's P/E ratio is -24.70. In terms of profitability, SCPH's ROE is -7.54%, compared to ASND's ROE of +1.91%. Regarding short-term risk, SCPH is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs RXDX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, RXDX has a market cap of 9.56B. Regarding current trading prices, SCPH is priced at $3.52, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SCPH's ROE is -7.54%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SCPH is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs IMGN Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, IMGN has a market cap of 8.73B. Regarding current trading prices, SCPH is priced at $3.52, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SCPH's ROE is -7.54%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, SCPH is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs CERE Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, CERE has a market cap of 8.19B. Regarding current trading prices, SCPH is priced at $3.52, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas CERE's P/E ratio is -16.47. In terms of profitability, SCPH's ROE is -7.54%, compared to CERE's ROE of -0.99%. Regarding short-term risk, SCPH is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs CORT Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, CORT has a market cap of 7.93B. Regarding current trading prices, SCPH is priced at $3.52, while CORT trades at $74.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas CORT's P/E ratio is 65.06. In terms of profitability, SCPH's ROE is -7.54%, compared to CORT's ROE of +0.20%. Regarding short-term risk, SCPH is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ROIVW Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ROIVW has a market cap of 7.83B. Regarding current trading prices, SCPH is priced at $3.52, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, SCPH's ROE is -7.54%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, SCPH is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ROIV Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ROIV has a market cap of 7.73B. Regarding current trading prices, SCPH is priced at $3.52, while ROIV trades at $10.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ROIV's P/E ratio is -10.84. In terms of profitability, SCPH's ROE is -7.54%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, SCPH is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs TECH Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, TECH has a market cap of 7.73B. Regarding current trading prices, SCPH is priced at $3.52, while TECH trades at $49.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas TECH's P/E ratio is 59.37. In terms of profitability, SCPH's ROE is -7.54%, compared to TECH's ROE of +0.06%. Regarding short-term risk, SCPH is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs RVMD Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, RVMD has a market cap of 7.44B. Regarding current trading prices, SCPH is priced at $3.52, while RVMD trades at $39.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas RVMD's P/E ratio is -9.96. In terms of profitability, SCPH's ROE is -7.54%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, SCPH is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs JAZZ Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, JAZZ has a market cap of 6.77B. Regarding current trading prices, SCPH is priced at $3.52, while JAZZ trades at $109.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas JAZZ's P/E ratio is 14.92. In terms of profitability, SCPH's ROE is -7.54%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, SCPH is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs HALO Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, HALO has a market cap of 6.57B. Regarding current trading prices, SCPH is priced at $3.52, while HALO trades at $53.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas HALO's P/E ratio is 14.17. In terms of profitability, SCPH's ROE is -7.54%, compared to HALO's ROE of +1.22%. Regarding short-term risk, SCPH is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs RETA Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, RETA has a market cap of 6.57B. Regarding current trading prices, SCPH is priced at $3.52, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas RETA's P/E ratio is -66.29. In terms of profitability, SCPH's ROE is -7.54%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SCPH is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs BPMC Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, BPMC has a market cap of 6.54B. Regarding current trading prices, SCPH is priced at $3.52, while BPMC trades at $101.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas BPMC's P/E ratio is -40.32. In terms of profitability, SCPH's ROE is -7.54%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, SCPH is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs MDGL Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, MDGL has a market cap of 6.45B. Regarding current trading prices, SCPH is priced at $3.52, while MDGL trades at $290.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas MDGL's P/E ratio is -16.30. In terms of profitability, SCPH's ROE is -7.54%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, SCPH is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs BBIO Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, BBIO has a market cap of 6.40B. Regarding current trading prices, SCPH is priced at $3.52, while BBIO trades at $33.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas BBIO's P/E ratio is -9.46. In terms of profitability, SCPH's ROE is -7.54%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, SCPH is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs VRNA Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, VRNA has a market cap of 6.17B. Regarding current trading prices, SCPH is priced at $3.52, while VRNA trades at $72.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas VRNA's P/E ratio is -36.29. In terms of profitability, SCPH's ROE is -7.54%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, SCPH is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs TLX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, TLX has a market cap of 5.62B. Regarding current trading prices, SCPH is priced at $3.52, while TLX trades at $16.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas TLX's P/E ratio is 186.56. In terms of profitability, SCPH's ROE is -7.54%, compared to TLX's ROE of +0.14%. Regarding short-term risk, SCPH is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs TGTX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, TGTX has a market cap of 5.55B. Regarding current trading prices, SCPH is priced at $3.52, while TGTX trades at $34.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas TGTX's P/E ratio is 139.92. In terms of profitability, SCPH's ROE is -7.54%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, SCPH is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ABCM Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ABCM has a market cap of 5.52B. Regarding current trading prices, SCPH is priced at $3.52, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SCPH's ROE is -7.54%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SCPH is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ISEE Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ISEE has a market cap of 5.51B. Regarding current trading prices, SCPH is priced at $3.52, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SCPH's ROE is -7.54%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SCPH is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs IONS Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, IONS has a market cap of 5.42B. Regarding current trading prices, SCPH is priced at $3.52, while IONS trades at $34.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas IONS's P/E ratio is -11.38. In terms of profitability, SCPH's ROE is -7.54%, compared to IONS's ROE of -0.00%. Regarding short-term risk, SCPH is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs AXSM Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, AXSM has a market cap of 5.33B. Regarding current trading prices, SCPH is priced at $3.52, while AXSM trades at $108.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas AXSM's P/E ratio is -18.77. In terms of profitability, SCPH's ROE is -7.54%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, SCPH is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs NUVL Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, NUVL has a market cap of 5.26B. Regarding current trading prices, SCPH is priced at $3.52, while NUVL trades at $73.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas NUVL's P/E ratio is -16.59. In terms of profitability, SCPH's ROE is -7.54%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, SCPH is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ALKS Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ALKS has a market cap of 5.19B. Regarding current trading prices, SCPH is priced at $3.52, while ALKS trades at $31.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ALKS's P/E ratio is 14.98. In terms of profitability, SCPH's ROE is -7.54%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, SCPH is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ADMA Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ADMA has a market cap of 4.82B. Regarding current trading prices, SCPH is priced at $3.52, while ADMA trades at $20.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ADMA's P/E ratio is 24.04. In terms of profitability, SCPH's ROE is -7.54%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, SCPH is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ALPN Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ALPN has a market cap of 4.46B. Regarding current trading prices, SCPH is priced at $3.52, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SCPH's ROE is -7.54%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, SCPH is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs OPT Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, OPT has a market cap of 4.20B. Regarding current trading prices, SCPH is priced at $3.52, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas OPT's P/E ratio is -1.52. In terms of profitability, SCPH's ROE is -7.54%, compared to OPT's ROE of +2.60%. Regarding short-term risk, SCPH is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs PCVX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, PCVX has a market cap of 4.13B. Regarding current trading prices, SCPH is priced at $3.52, while PCVX trades at $32.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas PCVX's P/E ratio is -8.03. In terms of profitability, SCPH's ROE is -7.54%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, SCPH is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs MRTX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, MRTX has a market cap of 4.12B. Regarding current trading prices, SCPH is priced at $3.52, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SCPH's ROE is -7.54%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, SCPH is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs RYTM Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, RYTM has a market cap of 3.90B. Regarding current trading prices, SCPH is priced at $3.52, while RYTM trades at $61.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas RYTM's P/E ratio is -21.87. In terms of profitability, SCPH's ROE is -7.54%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, SCPH is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs KRYS Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, KRYS has a market cap of 3.82B. Regarding current trading prices, SCPH is priced at $3.52, while KRYS trades at $132.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas KRYS's P/E ratio is 31.72. In terms of profitability, SCPH's ROE is -7.54%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, SCPH is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs RYZB Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, RYZB has a market cap of 3.75B. Regarding current trading prices, SCPH is priced at $3.52, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SCPH's ROE is -7.54%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SCPH is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs SRPT Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, SRPT has a market cap of 3.73B. Regarding current trading prices, SCPH is priced at $3.52, while SRPT trades at $37.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas SRPT's P/E ratio is -14.37. In terms of profitability, SCPH's ROE is -7.54%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, SCPH is more volatile compared to SRPT. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs CBAY Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, CBAY has a market cap of 3.73B. Regarding current trading prices, SCPH is priced at $3.52, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SCPH's ROE is -7.54%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, SCPH is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs PTCT Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, PTCT has a market cap of 3.72B. Regarding current trading prices, SCPH is priced at $3.52, while PTCT trades at $46.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas PTCT's P/E ratio is 7.21. In terms of profitability, SCPH's ROE is -7.54%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, SCPH is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ACAD Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ACAD has a market cap of 3.68B. Regarding current trading prices, SCPH is priced at $3.52, while ACAD trades at $21.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ACAD's P/E ratio is 16.05. In terms of profitability, SCPH's ROE is -7.54%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, SCPH is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs CYTK Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, CYTK has a market cap of 3.67B. Regarding current trading prices, SCPH is priced at $3.52, while CYTK trades at $30.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas CYTK's P/E ratio is -5.81. In terms of profitability, SCPH's ROE is -7.54%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, SCPH is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs RNA Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, RNA has a market cap of 3.64B. Regarding current trading prices, SCPH is priced at $3.52, while RNA trades at $30.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas RNA's P/E ratio is -10.07. In terms of profitability, SCPH's ROE is -7.54%, compared to RNA's ROE of -0.27%. Regarding short-term risk, SCPH is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs SWTX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, SWTX has a market cap of 3.49B. Regarding current trading prices, SCPH is priced at $3.52, while SWTX trades at $46.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas SWTX's P/E ratio is -13.57. In terms of profitability, SCPH's ROE is -7.54%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, SCPH is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs RARE Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, RARE has a market cap of 3.42B. Regarding current trading prices, SCPH is priced at $3.52, while RARE trades at $36.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas RARE's P/E ratio is -6.21. In terms of profitability, SCPH's ROE is -7.54%, compared to RARE's ROE of -1.86%. Regarding short-term risk, SCPH is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs CRSP Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, CRSP has a market cap of 3.34B. Regarding current trading prices, SCPH is priced at $3.52, while CRSP trades at $38.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas CRSP's P/E ratio is -8.61. In terms of profitability, SCPH's ROE is -7.54%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, SCPH is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ACLX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ACLX has a market cap of 3.22B. Regarding current trading prices, SCPH is priced at $3.52, while ACLX trades at $58.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ACLX's P/E ratio is -19.57. In terms of profitability, SCPH's ROE is -7.54%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, SCPH is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs SLNO Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, SLNO has a market cap of 3.21B. Regarding current trading prices, SCPH is priced at $3.52, while SLNO trades at $69.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas SLNO's P/E ratio is -15.97. In terms of profitability, SCPH's ROE is -7.54%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, SCPH is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs VKTX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, VKTX has a market cap of 3.09B. Regarding current trading prices, SCPH is priced at $3.52, while VKTX trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas VKTX's P/E ratio is -23.71. In terms of profitability, SCPH's ROE is -7.54%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, SCPH is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs MTSR Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, MTSR has a market cap of 3.04B. Regarding current trading prices, SCPH is priced at $3.52, while MTSR trades at $28.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas MTSR's P/E ratio is -11.40. In terms of profitability, SCPH's ROE is -7.54%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, SCPH is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs AKRO Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, AKRO has a market cap of 3.04B. Regarding current trading prices, SCPH is priced at $3.52, while AKRO trades at $38.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas AKRO's P/E ratio is -10.17. In terms of profitability, SCPH's ROE is -7.54%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, SCPH is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs CPRX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, CPRX has a market cap of 3.01B. Regarding current trading prices, SCPH is priced at $3.52, while CPRX trades at $24.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas CPRX's P/E ratio is 15.69. In terms of profitability, SCPH's ROE is -7.54%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, SCPH is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs CRNX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, CRNX has a market cap of 2.90B. Regarding current trading prices, SCPH is priced at $3.52, while CRNX trades at $30.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas CRNX's P/E ratio is -8.14. In terms of profitability, SCPH's ROE is -7.54%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, SCPH is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs SRRK Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, SRRK has a market cap of 2.86B. Regarding current trading prices, SCPH is priced at $3.52, while SRRK trades at $30.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas SRRK's P/E ratio is -11.83. In terms of profitability, SCPH's ROE is -7.54%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, SCPH is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs MRUS Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, MRUS has a market cap of 2.86B. Regarding current trading prices, SCPH is priced at $3.52, while MRUS trades at $41.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas MRUS's P/E ratio is -9.94. In terms of profitability, SCPH's ROE is -7.54%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, SCPH is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs MORF Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, MORF has a market cap of 2.86B. Regarding current trading prices, SCPH is priced at $3.52, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas MORF's P/E ratio is -14.88. In terms of profitability, SCPH's ROE is -7.54%, compared to MORF's ROE of -0.27%. Regarding short-term risk, SCPH is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs MOR Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, MOR has a market cap of 2.86B. Regarding current trading prices, SCPH is priced at $3.52, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas MOR's P/E ratio is -12.64. In terms of profitability, SCPH's ROE is -7.54%, compared to MOR's ROE of +7.43%. Regarding short-term risk, SCPH is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs PTGX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, PTGX has a market cap of 2.82B. Regarding current trading prices, SCPH is priced at $3.52, while PTGX trades at $45.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas PTGX's P/E ratio is 58.42. In terms of profitability, SCPH's ROE is -7.54%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, SCPH is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs KDNY Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, KDNY has a market cap of 2.71B. Regarding current trading prices, SCPH is priced at $3.52, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas KDNY's P/E ratio is -12.47. In terms of profitability, SCPH's ROE is -7.54%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, SCPH is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs LEGN Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, LEGN has a market cap of 2.68B. Regarding current trading prices, SCPH is priced at $3.52, while LEGN trades at $29.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas LEGN's P/E ratio is -24.67. In terms of profitability, SCPH's ROE is -7.54%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, SCPH is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs MYOV Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, MYOV has a market cap of 2.62B. Regarding current trading prices, SCPH is priced at $3.52, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas MYOV's P/E ratio is -14.05. In terms of profitability, SCPH's ROE is -7.54%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, SCPH is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs IMVT Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, IMVT has a market cap of 2.50B. Regarding current trading prices, SCPH is priced at $3.52, while IMVT trades at $14.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas IMVT's P/E ratio is -5.61. In terms of profitability, SCPH's ROE is -7.54%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, SCPH is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs MLTX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, MLTX has a market cap of 2.49B. Regarding current trading prices, SCPH is priced at $3.52, while MLTX trades at $39.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas MLTX's P/E ratio is -17.04. In terms of profitability, SCPH's ROE is -7.54%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, SCPH is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs IBRX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, IBRX has a market cap of 2.47B. Regarding current trading prices, SCPH is priced at $3.52, while IBRX trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas IBRX's P/E ratio is -4.91. In terms of profitability, SCPH's ROE is -7.54%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, SCPH is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs APGE Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, APGE has a market cap of 2.38B. Regarding current trading prices, SCPH is priced at $3.52, while APGE trades at $39.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas APGE's P/E ratio is -11.06. In terms of profitability, SCPH's ROE is -7.54%, compared to APGE's ROE of -0.19%. Regarding short-term risk, SCPH is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs PRVB Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, PRVB has a market cap of 2.38B. Regarding current trading prices, SCPH is priced at $3.52, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas PRVB's P/E ratio is -16.43. In terms of profitability, SCPH's ROE is -7.54%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, SCPH is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs XENE Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, XENE has a market cap of 2.37B. Regarding current trading prices, SCPH is priced at $3.52, while XENE trades at $30.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas XENE's P/E ratio is -9.61. In terms of profitability, SCPH's ROE is -7.54%, compared to XENE's ROE of -0.32%. Regarding short-term risk, SCPH is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs LBPH Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, LBPH has a market cap of 2.34B. Regarding current trading prices, SCPH is priced at $3.52, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas LBPH's P/E ratio is -26.66. In terms of profitability, SCPH's ROE is -7.54%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, SCPH is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs VCYT Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, VCYT has a market cap of 2.27B. Regarding current trading prices, SCPH is priced at $3.52, while VCYT trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas VCYT's P/E ratio is 69.05. In terms of profitability, SCPH's ROE is -7.54%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, SCPH is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs DICE Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, DICE has a market cap of 2.27B. Regarding current trading prices, SCPH is priced at $3.52, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas DICE's P/E ratio is -21.91. In terms of profitability, SCPH's ROE is -7.54%, compared to DICE's ROE of +0.56%. Regarding short-term risk, SCPH is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs MIRM Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, MIRM has a market cap of 2.22B. Regarding current trading prices, SCPH is priced at $3.52, while MIRM trades at $44.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas MIRM's P/E ratio is -27.88. In terms of profitability, SCPH's ROE is -7.54%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, SCPH is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs APLS Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, APLS has a market cap of 2.22B. Regarding current trading prices, SCPH is priced at $3.52, while APLS trades at $17.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas APLS's P/E ratio is -9.82. In terms of profitability, SCPH's ROE is -7.54%, compared to APLS's ROE of -1.00%. Regarding short-term risk, SCPH is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs ARWR Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, ARWR has a market cap of 2.17B. Regarding current trading prices, SCPH is priced at $3.52, while ARWR trades at $15.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas ARWR's P/E ratio is -12.69. In terms of profitability, SCPH's ROE is -7.54%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, SCPH is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs BCRX Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, BCRX has a market cap of 2.17B. Regarding current trading prices, SCPH is priced at $3.52, while BCRX trades at $10.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas BCRX's P/E ratio is -39.88. In terms of profitability, SCPH's ROE is -7.54%, compared to BCRX's ROE of +0.15%. Regarding short-term risk, SCPH is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs CALT Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, CALT has a market cap of 2.15B. Regarding current trading prices, SCPH is priced at $3.52, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas CALT's P/E ratio is -22.73. In terms of profitability, SCPH's ROE is -7.54%, compared to CALT's ROE of -2.10%. Regarding short-term risk, SCPH is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs VCEL Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, VCEL has a market cap of 2.14B. Regarding current trading prices, SCPH is priced at $3.52, while VCEL trades at $42.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas VCEL's P/E ratio is 850.80. In terms of profitability, SCPH's ROE is -7.54%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, SCPH is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs NAMS Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, NAMS has a market cap of 2.14B. Regarding current trading prices, SCPH is priced at $3.52, while NAMS trades at $19.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas NAMS's P/E ratio is -10.34. In terms of profitability, SCPH's ROE is -7.54%, compared to NAMS's ROE of -0.26%. Regarding short-term risk, SCPH is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs BLTE Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, BLTE has a market cap of 2.12B. Regarding current trading prices, SCPH is priced at $3.52, while BLTE trades at $65.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas BLTE's P/E ratio is -47.79. In terms of profitability, SCPH's ROE is -7.54%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, SCPH is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs AAPG Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, AAPG has a market cap of 2.06B. Regarding current trading prices, SCPH is priced at $3.52, while AAPG trades at $23.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas AAPG's P/E ratio is -32.14. In terms of profitability, SCPH's ROE is -7.54%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, SCPH is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs HRMY Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, HRMY has a market cap of 2.06B. Regarding current trading prices, SCPH is priced at $3.52, while HRMY trades at $35.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas HRMY's P/E ratio is 13.71. In terms of profitability, SCPH's ROE is -7.54%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, SCPH is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs LGND Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, LGND has a market cap of 2.03B. Regarding current trading prices, SCPH is priced at $3.52, while LGND trades at $105.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas LGND's P/E ratio is -14.45. In terms of profitability, SCPH's ROE is -7.54%, compared to LGND's ROE of -0.16%. Regarding short-term risk, SCPH is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs DNLI Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, DNLI has a market cap of 2.02B. Regarding current trading prices, SCPH is priced at $3.52, while DNLI trades at $13.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas DNLI's P/E ratio is -5.21. In terms of profitability, SCPH's ROE is -7.54%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, SCPH is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs FOLD Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, FOLD has a market cap of 1.98B. Regarding current trading prices, SCPH is priced at $3.52, while FOLD trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas FOLD's P/E ratio is -71.33. In terms of profitability, SCPH's ROE is -7.54%, compared to FOLD's ROE of -0.17%. Regarding short-term risk, SCPH is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs KYMR Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, KYMR has a market cap of 1.97B. Regarding current trading prices, SCPH is priced at $3.52, while KYMR trades at $30.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas KYMR's P/E ratio is -9.71. In terms of profitability, SCPH's ROE is -7.54%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, SCPH is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs KNSA Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, KNSA has a market cap of 1.95B. Regarding current trading prices, SCPH is priced at $3.52, while KNSA trades at $26.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas KNSA's P/E ratio is -111.42. In terms of profitability, SCPH's ROE is -7.54%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, SCPH is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs NAMSW Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, NAMSW has a market cap of 1.94B. Regarding current trading prices, SCPH is priced at $3.52, while NAMSW trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas NAMSW's P/E ratio is N/A. In terms of profitability, SCPH's ROE is -7.54%, compared to NAMSW's ROE of -0.26%. Regarding short-term risk, SCPH is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.
SCPH vs CGON Comparison
SCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCPH stands at 185.83M. In comparison, CGON has a market cap of 1.89B. Regarding current trading prices, SCPH is priced at $3.52, while CGON trades at $24.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCPH currently has a P/E ratio of -1.83, whereas CGON's P/E ratio is -16.57. In terms of profitability, SCPH's ROE is -7.54%, compared to CGON's ROE of -0.11%. Regarding short-term risk, SCPH is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for SCPH.